Cosmetic cross-reference

Alanine

CAS 56-41-7

Alanine (CAS 56-41-7) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 2 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Alanine

CAS Number

56-41-7

UNII

OF5P57N2ZX

InChIKey

QNAYBMKLOCPYGJ-REOHCLBHSA-N

ChEMBL ID

CHEMBL279597

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

L-alanine

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL279597 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	30000 nM	31	-
-	MIC	18846.153846153848 nM	13	-
-	IC50	69000 nM	2	-
-	Potency	1433.3500000000001 nM	2	-

SOURCE DrugCentral 2 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Foetal growth restriction	15	71.678	10070531
Device related sepsis	10	50.99	10069802

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
GPRC6 GPRC6A	Full agonist	3.8 pEC50	15576628

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Alanine	426	SU	MTHSPL
ALANINE	426	SU	MTHSPL
alanine	426	IN	RXNORM
L-alanine	426	SY	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Alanine used for in pharmaceutical contexts?

Alanine (CAS 56-41-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Alanine?

Alanine has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Device related sepsis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Alanine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for L-Alanine with EU status "permitted".

What clinical phase is Alanine in?

Alanine is rendered with ChEMBL max phase 3.